Ropeg is a novel PEGylated IFN-α-based therapy approved for the treatment of a myeloproliferative neoplasm, polycythemia vera, and can potentially activate a network of tumor suppressors or their related proteins by binding to IFN receptors on tumor cells to inhibit the neoplastic phenotype [16]. Here, IFNA1 is linked to acquired polycythemia vera.